Supplemental Figure 4 from Increased Glucose Availability Sensitizes Pancreatic Cancer to Macrophage-Targeting Immunotherapies

Le résumé fourni par la source

Supplemental Figure 4 - Macrophage-targeting immunotherapies are associated with a protective effect for M1-like macrophage polarization in vitro without impacting macrophage viability. A.) Western blot of M0, M1-, and M2-like macrophages treated with vehicle or PLX3397 (100 nm) in high (25 mM) or low (1 mM) glucose conditions for 48 hours. B.) Baseline western blot of CSF1R and CCR2 in M0, M1-, and M2-like macrophages. C.) Western blot of CSF1R of M1- and M2-like macrophages in high and low glucose conditions. D.) Western blot of M1- and M2-like macrophages treated with vehicle or PF-4136309 (100 nm) in high (25 mM) or low (1 mM) glucose conditions for 48 hours. Protein quantification is normalized to α-Tubulin unless otherwise shown. E.) Bone marrow-derived macrophage survival (M1- and M2-like) treated with varying concentrations of PLX3397 (left) or PF-4136309 (right) in high (25 mM) or low (1 mM) glucose conditions after 4 days assessed via double-stranded DNA quantification (PicoGreen). F.) KPC cell survival treated with varying concentrations of PLX3397 in high (25 mM) or low (2.5 mM) glucose after 4 days assessed via double-stranded DNA quantification (PicoGreen).

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.